March 30, 2022
Article
Furthermore, psoriatic treatment did not appear to significantly reduce COVID-19 vaccine efficacy.
March 29, 2022
A new AAD study shows board-certified experts produce only one-fourth of the most popular TikTok posts on subjects in their field.
March 28, 2022
An assessment of long-term VOYAGER 1 and 2 trial data show the IL-23 biologic provides significant benefit toward skin clearance, regardless of baseline characteristics.
The VALIANT study featured a cross-sectional online survey that was used to recruit adult patients 18 years and older who were professionally diagnosed with vitiligo.
Data from the ADhere studies found that lebrikizumab was well tolerated in patients with atopic dermatitis.
Video
A pair of novel topical drugs hit high phase 3 marks at AAD 2022. One expert explains how they both may reach ground-breaking indications.
Clinical responses including PASI 100 and absolute PASI, and PASI ≤2 were maintained through week 96 with the biologic in patients with psoriasis, with no new safety signals identified.
New AAD 2022 data support the novel gel therapy as the potentially first treatment for the viral-borne skin condition.
March 27, 2022
The new oral medicine helped some patients with mild to moderate psoriasis achieve and sustain PASI-50 after the initial study period.
Amy S. Paller, MD, concludes her AAD 2022 interview with a look into the future of pediatric systemic therapy—and a call to assure due diligence in tracking patient progression among her peers.
Study Suggests Sickle Cell Trait as an Adverse Prognostic Factor for COVID-19
Atherosclerotic Plaque Found Highly Prevalent in Older Population in China
Vurolenatide Showing Promise Treating Short Bowel Syndrome
